Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
نویسندگان
چکیده
منابع مشابه
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
BACKGROUND Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-containing cytokines inc...
متن کاملVitiligo Repigmentation: What’s New?
Vitiligo is a relatively common acquired skin disorder, characterized by the progressive loss of melanocytes, which results in white patches. Classically, vitiligo’s treatments have been considered unsatisfactory and challenging. Recent advances in the knowledge of vitiligo’s pathogenesis have contributed to find better therapeutic options, so that at present many patients find a solution for d...
متن کاملThe pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Tofacitinib is a novel, oral Janus kinase inhibitor. The objectives of this study were to summarize the pharmacokinetics and metabolism of tofacitinib in humans, including clearance mechanisms. Following administration of a single 50-mg (14)C-labeled tofacitinib dose to healthy male subjects, the mean (standard deviation) total percentage of administered radioactive dose recovered was 93.9% (±3...
متن کاملOral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Since the introduction of immune modulators in the treatment of rheumatoid arthritis (RA), there has been hope that orally effective biologic agents would be developed. Tofacitinib, a Janus kinase inhibitor, has become the first oral biologic to receive approval for use in active RA patients. This paper reviews the efficacy and safety profile of Tofacitinib at dosages of 5 mg and 10 mg twice da...
متن کاملTofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
OBJECTIVES Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To further assess the potential role of Janus kinase inhibition in the development of malignancies, we performed an integrated analysis of data from the tofacitinib RA clinical development programme. METHODS Malignancy data (up to 10 April 2013) were pooled from six phase II, six Phase III...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Academy of Dermatology
سال: 2017
ISSN: 0190-9622
DOI: 10.1016/j.jaad.2017.05.043